Articles By Jack Cush, MD
Steroids in GCA and PMR Increase Infectious Risk
A large study of UK family practice patients shows that polymyalgia rheumatica (PMR) or giant cell arteritis (GCA) patients treated with glucocorticoids are at an increased risk of bacterial, viral, parasitic and fungal infection, even at daily doses of less than 5 mg prednisolone.
Read Article
RheumNow Podcast – Late Breaking Abstract Wrap-Up (6.21.19)
Dr. Jack Cush reviews the week’s news and wrap up from EULAR19.
Read Article
EULAR 2019 - Podcast #1
This EULAR 2019 Podcast is a compilation of audio clips from EULAR 2019 in Madrid. Click HERE to listen.
Read Article
No Difference Among Biologics in Arthroplasty Infectious Risk
A large administrative claims analysis of rheumatoid arthritis (RA) patients undergoing arthroplasty has shown no difference among biologics with regard to the risk of infections, but corticosteroid use was associated with a dose dependent risk of infection.
Read Article
Allopurinol Fails to Curtail Hypertension
A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative. Hypertension is one of the many comorbidities that plagues gout patients.
Read Article
ACP Guidelines on Developing Evidence Based Clinical Guidelines
Recommendations for the screening, diagnosis, and treatment of various diseases often differ by organization, making it difficult to know which ones to follow.
Read Article
Borrelia burgdorferi Peptidoglycan Shedding Drives Lyme Arthritis
Research published in PNAS has shown that long after active Lyme infection in the joint, a peptidoglycan (PG) of the the spirochete Borrelia burgdorferi can be found in the joints of those with late-stage Lyme disease.
Read Article
EULAR 2019- Day 4 Report
Saturday June 15th was the last half-day at EULAR 2019 but was highlighted by the “late-breaking” (LB) presentations that were presented from the podium and by poster. Below are the top “LB” presentations from EULAR this year:
Read Article
EULAR 2019 – Day 3 Report
The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day.
Read Article
RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)
Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019. 1. Genovese Vagal nerve stimulator in RA
Read Article
